摘要
目的观察替格瑞洛对急性ST段抬高型心肌梗死(STEMI)的临床效果,并与氯吡格雷对比,获取前瞻性临床数据。方法入选我院STEMI患者200例,随机分为两组,每组100人,对照组给予氯吡格雷+阿司匹林治疗,观察组给予替格瑞洛+阿司匹林治疗。分别于治疗后1个月、3个月、6个月电话随访观察两组患者的常规指标以及主要不良心血管事件发生率。结果替格瑞洛组与氯吡格雷组相比,左心室射血分数(EF)、ST段回落及血小板水平均,P<0.05,差异具有统计学意义,MACE发生率两组之间,P>0.05,差异不具有统计学意义。不良反应两组,P>0.05,差异不具有统计学意义。结论替格瑞洛在STEMI患者治疗中,效果与氯吡格雷无差异,不良反应发生率无差异,可安全应用。
Objective To observe the Ticagrelor for acute ST segment elevation myocardial infarction （STEMI） clinical effect.Methods 200 STEMI patients in our hospital, separated into two groups randomly, the control group was given clopidogrel plus aspirin treatment, the observation group was given for Ticagrelor and aspirin therapy, telephone follow for treatment.Results for the green Luo group compared with clopidogrel group, left ventricular ejection fraction （EF）, ST segment resolution and platelet levels were statistically significant difference （P〈0.05）, the incidence of MACE between the two groups had no signiifcant difference （P〉0.05）.Conclusion for Grillo in the STEMI in the treatment of patients with clopidogrel, no difference in effect, adverse reaction rate of no difference, it can be safely used.
出处
《中国继续医学教育》
2015年第10期212-212,共1页
China Continuing Medical Education
关键词
ST段抬高型
心肌梗死
替格瑞洛
氯吡格雷
ST segment elevation
Myocardial infarction
Ticagrelor
Clopidogrel
